Diabetes tech companies continue 2020's success with Q1 growth. Investors seem unimpressed.

Diabetes tech companies continue 2020's success with Q1 growth. Investors seem unimpressed.

Source: 
Medtech Dive
snippet: 

Dexcom, Insulet and Tandem all grew revenue or sales in Q1, winning over Wall Street analysts but seemingly not investors. Meanwhile, the diabetes tech space grows with Bigfoot Biomedical clearance.